This review provides a compendium of retrievable results of genotoxicity and animal carcinogenicity studies performed of antibacterial, antiviral, antimalarial and antifungal drugs of long-term or intermittent frequent use. Of the 48 drugs considered, 9 (18.75%) do not have retrievable data, whereas the other 39 (81.25%) have at least one genotoxicity or carcinogenicity tests result. Of these 39 drugs, 24 tested positive in at least one genotoxicity assay and 19 in at least one carcinogenicity assay; 14 of them gave a positive response in both at least one genotoxicity assay and at least one carcinogenicity assay. Concerning the predictivity of genetic toxicology findings for the results of long-term carcinogenesis assays, of 23 drugs with both genotoxicity and carcinogenicity data: 2 (8.7%) were neither genotoxic nor carcinogenic, 2 (8.7%) tested positive in at least one genotoxicity assay but were non-carcinogenic, 4 (17.4%) tested negative in genotoxicity assays but were carcinogenic, and 15 (65.2%) gave a positive response in at least one genotoxicity assay and in at least one carcinogenicity assay. Only 18 (37.5%) of the 48 drugs examined had all data required by present guidelines for testing of pharmaceuticals, but a fraction of them (49%) were developed and marketed prior to the present regulatory climate. In the absence of compelling indications, the prescription of the 19 drugs that are animal carcinogens should be avoided.
Introduction
Several antibacterial, antiviral, antimalarial and antifungal drugs are pharmaceuticals of long-term clinical use or are used frequently in an intermittent manner. Among the various adverse reactions that these drugs may cause, the occurrence of genotoxic and carcinogenic effects cannot be excluded. The regulatory authorities of Europe, USA and Japan recommend that genotoxicity and carcinogenicity studies are performed as part of an application for marketing approval of pharmaceuticals. Current guidelines for genotoxicity testing of pharmaceuticals (1-3) prescribe a standard test battery that consists of: (i) a test for gene mutation in bacteria, (ii) an in vitro test with cytogenetic evaluation of chromosomal damage with mammalian cells or an in vitro mammalian cells gene mutation assay and (iii) an in vivo test for chromosomal damage using rodent haematopoietic cells. Guidelines for carcinogenicity testing of pharmaceuticals (4, 5) indicate that long-term carcinogenicity studies in rodents should be performed for all pharmaceuticals whose expected clinical use is continuous for at least 6 months as well as for pharmaceuticals used frequently in an intermittent manner in the treatment of chronic recurrent conditions. In longterm carcinogenicity assays, the highest dose should be at least 25-fold higher, on a milligram per square millimetre basis, than the maximum recommended human daily dose or represent a 25-fold ratio of rodent to human area under the curve.
In the 2007 edition of the Martindale-The Complete Drug Reference (6) there are 48 antibacterial, antiviral, antimalarial and antifungal drugs that would require genotoxicity and carcinogenicity testing, but 21 of them were developed prior to the present regulatory climate. Most of them are marketed in several countries. In a review of Snyder and Green (7) on the genotoxicity of marketed pharmaceuticals, based on information obtained by the 1999 edition of the Physicians' Desk Reference as well as from the peer-reviewed published literature, there are only 16 of the above-mentioned 48 drugs, but only 13 have all data required by present guidelines on genotoxicity and carcinogenicity testing. The International Agency for Research on Cancer (IARC) (8) in the 99 volumes of the IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, that were published in the years from 1972 to 2010, examined .200 drugs, but these include only 15 of the 48 pharmaceuticals considered in this review: acyclovir, ampicillin, chloramphenicol, chloroquine, dapsone, didanosine, ethionamide, griseofulvin, isoniazid, metronidazole, nitrofurantoin, nitrofurazone, rifampicin, zalcitabine and zidovudine. These data indicate that in prescribing the large majority of the 48 drugs considered, the evaluation of the benefit/genotoxic-carcinogenic effects ratio is impossible. Therefore, we deemed it useful to examine whether data allowing more complete evaluation can be retrieved.
This review is a compendium of all the genotoxicity and carcinogenicity data that have been found in an extensive search. For each drug considered, search terms associated with genotoxic activity and carcinogenic activity were used. The search was conducted primarily in peer-reviewed journals using Medline, Toxline and the Registry of Toxic Effects of Chemical Substances (9) . Additional unpublished data were obtained from the following websites: http://www.toxnet.nlm.nih.gov, http:// www.ntp.server.niehs.nih.gov, http://www.potency.berkeley.edu, http://www.fda.gov/cder, http://www.scirus.com, http://www. inchem.org, http://www.updateusa.com and http://www.osha.gov. Concerning data that are not published in peer-reviewed journals, in some cases the tests were conducted under the supervision of authoritative bodies, such as the US National Toxicology Program; in the other cases, the genotoxicity and carcinogenicity data are those reported by the Physician's Desk Reference (10) or in the final package insert approved by the Centre for Drug Evaluation and Research of the Food and Drug Administration. Unfortunately, this additional unpublished information is often incomplete; in particular, the results of genotoxicity assays are usually reported without any information of the doses that have been tested. Moreover, often no information is given whether the in vitro genotoxicity assays were performed in both the presence and the absence of an exogenous metabolic system; in these cases, taking into account that this procedure is required by the guidelines, in the absence of a specific indication the published value is reported in the tables as obtained in both these experimental conditions.
Results of genotoxicity and animal carcinogenicity assays
Information about genotoxicity and/or carcinogenicity was retrieved for 39 of the 48 antibacterial, antiviral, antimalarial and antifungal drugs considered in this review (Table I) . Only 18 drugs can be considered, on the basis of retrieved data, as tested in substantial agreement with the indications of the present guidelines on genotoxicity and carcinogenicity testing of pharmaceuticals. Of these 18 drugs: posaconazole gave negative results in all genotoxicity and carcinogenicity assays; acyclovir and lamivudine gave some evidence of genotoxicity but tested negative in carcinogenicity assays; delavirdine, indinavir, nevirapine and terbinafine tested negative in genotoxicity assays but gave positive results in carcinogenicity assays; chloramphenicol, dapsone, entecavir, griseofulvin, isoniazid, metronidazole, nitrofurantoin, nitrofurazone, stavudine, zalcitabine and zidovudine gave positive responses in both genotoxicity and carcinogenicity assays. Five additional drugs were tested for carcinogenicity but to a limited extent, i.e. not as recommended by present guidelines, for genotoxicity: clofazimine gave negative response in both genotoxicity and carcinogenicity assays; pyrazinamide tested positive in one genotoxicity assays but was non-carcinogenic; and ampicillin, ethionamide and rifampicin gave positive responses in both genotoxicity and carcinogenicity assays. Of 15 drugs, we retrieved only results of genotoxicity assays: amprenavir, azithromycin, cycloserine, efavirenz, emtricitabine, nelfinavir, rifapentine and ritonavir gave negative responses; 4-aminosalicylic acid, atazanavir, chloroquine, didanosine, ethambutol, streptomycin and tenofovir gave one or more than one positive response. Abacavir was carcinogenic in both mice and rats, but results of genotoxicity assays were not retrieved.
Of 9 drugs (18.75%), neither results of genotoxicity assays nor results of carcinogenicity assays were retrieved.
Epidemiological studies of cancer in humans
An extensive search dealing with the relationship between long-term or frequent intermittent therapy with antibacterials, antivirals, antimalarials and antifungals and carcinogenic risk to humans is beyond the aim of this review, but we deem it useful to summarize the results of the most interesting studies.
The results of one prospective study and an extensive observational follow-up indicate no increased risk for cancer among patients with recurrent herpes simplex given acyclovir, but no conclusions can be drawn since these studies were not designed to investigate cancer (12) . Ampicillin (15) , in a hypothesis-generating cohort study designed to screen 215 drugs for possible carcinogenicity was found to be associated with the occurrence of skin and lung cancer, but this association should further be verified. Numerous cases reports of leukaemia occurring following chloramphenicol-induced aplastic anaemia have been published (15) . Cases of cancer have been reported in patients treated with dapsone (59) . The most recent follow-up studies indicate an increased mortality restricted to males from cancer of the oral cavity and the bladder and for lymphoma (standardized mortality ratio 4.5, 4.0 and 3.0, respectively). No conclusions can be drawn about the carcinogenicity of didanosine from three trials designed to assess its efficacy in improving the degree of immunocompetence and survival of patients with HIV infection (12) . No sufficient data from human studies are considered available to exclude a carcinogenic risk of griseofulvin (68) . As a matter of fact, although an excess of thyroid cancer was reported among users of griseofulvin in a 9-year follow-up, no results for this drug were reported in a 15-year follow-up, thus implicating that no significant association was observed for cancer at any site (38) . Evidence for carcinogenicity to humans of isoniazid is considered by IARC inadequate (59) on the basis of the results of several studies. Two epidemiological studies of women treated with metronidazole showed some excess of cancer of the uterine cervix, and an excess of lung cancer was observed but only in one of these two studies (59) . Concerning nitrofurantoin (15) , in an hypothesis-generating cohort study increased risks were noted for cancer of the uterine corpus and other female genital organs, as well as for cancers of the nervous system. Moreover, a single case report has been published of focal nodular hyperplasia of the liver in a 6-yearold girl. No significant association was noted with cancer at any site or at all sites in patients treated with nitrofurazone (15) . The only data available for zalcitabine (12) are from two trials designed to assess its efficacy in improving the degree of immunocompetence and survival of patients with HIV infection and one phase I trial of zalcitabine with zidovudine, but no conclusions can be drawn concerning its carcinogenicity. Concerning zidovudine (12) , none of three studies provide information on the risk for cancer associated with its use for .3 years. Therefore, there is no conclusive evidence that these nucleoside analogues caused tumours in humans (69) . No case reports or epidemiological studies are available for ethionamide and rifampicin.
We are aware that data on the epidemiology of these drugs is likely to be incomplete and of the bias involved in choosing the most interesting studies.
Concerning the 15 drugs considered in IARC Monographs, 10 are judged as not classifiable as to their carcinogenicity to humans (Group 3): acyclovir, chloroquine and didanosine due to inadequate evidence of carcinogenicity in both animals and humans; ampicillin, dapsone and isoniazid, nitrofurantoin and nitrofurazone due to limited evidence of carcinogenicity in animals and inadequate evidence in humans; and ethionamide and rifampicin due to inadequate evidence of carcinogenicity in animals and limited evidence in humans. Griseofulvin, metronidazole and zalcitabine and zidovudine are judged as possibly carcinogenic to humans (Group 2B) due to inadequate evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals and chloramphenicol as probably carcinogenic to humans (Group 2A) due to limited evidence for carcinogenicity in humans and inadequate evidence of carcinogenicity in experimental animals. S. typhimurium TA1977, reverse mutation � NT 600 lg/ml (11, 18) S. typhimurium TA1535, TA1537, TA1538, reverse mutation � � 10 000 lg/plate (11, 18) S. typhimurium TA98, TA100, reverse mutation þ þ 0-10 000 lg/plate (11, 19) S. typhimurium TA98, TA100, TA1537, TA1538, reverse mutation NT � 5000 lg/plate (11, 20) S. typhimurium TA97A, TA1537, reverse mutation � � 5000 lg/plate (11, 21) S. typhimurium TA98, TA100, reverse mutation � � 50 lg/plate (11, 22) S. typhimurium TA97A, TA100, reverse mutation � � 10 000 lg/plate (11 Long-term carcinogenesis assay, C57BL6 mice mother and offspring � (�1.6) 100 mg/kg/day to mothers; 52 g/kg total dose in offspring (27) Long-term carcinogenesis assay, A/He mice ? 2.65 g/kg (total dose) (27) Long-term carcinogenesis assay, TgAC transgenic mice � 10% topically (24) Long-term carcinogenesis assay, F344 male rats þ (Sarcomas of spleen and peritoneum) 600 ppm in diet (11, 28, 29) Long-term carcinogenesis assay, F344 female rats � (�3.9) 1200 ppm in diet (11, 29, 30) Long-term carcinogenesis assay, BDIV rats mother and offspring þ (Thyroid tumours) 100 mg/kg/day to mothers; 52 g/kg total dose in offspring (11, 27) Long-term carcinogenesis assay, Wistar male rats þ (Tumours at multiple sites) 0.025-0.30% in diet (11, 21) Long-term carcinogenesis assay, rats � (�0.5) 15 mg/kg/day (24)
Long-term carcinogenesis assay, Sprague-Dawley female rats
Long-term carcinogenesis assay, Sprague-Dawley female rats � 30 mg/rat � 10 p.o.
13. Delavirdine (136817-59-9) S. typhimurium, reverse mutation 
Micronucleus test, (C57BL/6 � C3H) female mice bone marrow cells in vivo
Micronucleus test, BALB/c bone marrow cells in vivo
Micronucleus test, animal cells in vivo
Chromosomal aberrations, BALB/c mouse bone marrow cells in vivo
Genotoxicity and carcinogenicity Long-term carcinogenesis assay, C3Hf male mice � (�0.5) 0.06% in drinking water (27) Long-term carcinogenesis assay, C3Hf female mice þ (Liver tumours) 0.03% in drinking water (11, 27) Long-term carcinogenesis assay, BALB/c mice � (�0.5) 0.06% in drinking water (27) Long-term carcinogenesis assay, BALB/c mice � (�0.05) 0.3 mg/mouse s.c. (27) Long-term carcinogenesis assay, Wistar rats � (�1.0) 0.06% in drinking water (27) 
Cell transformation (cells not specified) þ NT 500 lg/ml
Chromosomal aberrations, human lymphocytes in vitro þ þ 1.5 lg/ml
Micronucleus test,
Micronucleus test, mice in vivo
Micronucleus test, mice in vivo � 0.12 mg/kg � 1
Long-term carcinogenesis assay, B6C3F1 female mice þ (Thymic lymphomas) 500 mg/kg/day (12) Long-term carcinogenesis assay, B6C3F1 male mice þ (Thymic lymphomas) 500 mg/kg/day (12) Long-term carcinogenesis assay, NIH Swiss mice þ (Thymomas) 500 mg/kg/day (12) 39. Zidovudine (30516-87-1)
E. coli, differential toxicity (þ) NT 1000 lg/ml (12) B. subtilis, differential toxicity � NT NR (12) S. typhimurium TA88, TA100, TA1535, TA1537, TA1538, reverse mutation
S. typhimurium TA97, TA98, TA100, TA104, TA1535, reverse mutation
B. subtilis, gene mutation � NT NR (12) Gene mutation, Chinese hamster ovary cells, hprt locus � NT 10000 lg/ml
Gene mutation, mouse lymphoma L5178Y cells, TK locus
Gene mutation, mouse lymphoma L5178Y cells, TK locus þ NT 25 lg/ml � 24 h
SCE, Chinese hamster cells in vitro þ NT 500 lg/ml
Chromosomal aberrations, Chinese hamster cells in vitro � NT 2500 lg/ml
Cell transformation, BALB/c 3T3 mouse cells þ NT 0.5 lg/ml
Gene mutation, human Hep/G2 cells, hprt locus þ NT 100 lg/ml
Gene mutation, human TK6 lymphoblastoid cells, TK locus þ NT 9 lg/ml � 3 days
Gene mutation, human TK6 lymphoblastoid cells, hprt locus þ NT 80 lg/ml � 3 days
SCE, human lymphocytes in vitro þ NT 50 lg/ml (12) Micronucleus test, human lymphocytes in vitro þ NT 500 lg/ml
Chromosomal aberrations, human lymphocytes in vitro þ NT 100 lg/ml (12) 
Chromosomal aberrations, rat bone marrow cells in vivo � 300 mg/kg i.v. � 1
Binding covalent to DNA of Chinese hamster ovary cells in vitro
Binding covalent to DNA of mouse NIH 3T3 cells in vitro
Binding covalent to DNA of CCRF/CEM human lymphoid cells in vitro
Binding covalent to DNA of human bone marrow cells in vitro
Binding covalent to DNA of K562 human leukaemic cells in vitro
Binding covalent to DNA of HL60 human leukaemic cells in vitro
Binding covalent to DNA of HCT8 human colon cancer cells in vitro
Binding covalent to DNA of H9human lymphocytic cells in vitro
Binding covalent to DNA of TK6 human lymphoblastoid cells in vitro
Binding covalent to DNA of mouse vaginal epithelial cells in vivo
Genotoxicity and carcinogenicity
Discussion
The present survey was performed to examine to what extent several antibacterial, antiviral, antimalarial and antifungal drugs of long-term or frequent intermittent use have been tested for their genotoxic and carcinogenic activity. It cannot be excluded that additional published results as well as unpublished results of difficult retrieval exist; notwithstanding we deem that information provided by this review is sufficient to give an overall perspective of the present knowledge and to allow some considerations about the possibility for the scientific community of evaluating the genotoxic-carcinogenic risk to humans and the corresponding benefit/risk ratio of the 48 pharmaceuticals examined. Table II indicates the number of drugs that underwent testing in the various types of genotoxicity assays: 37 drugs underwent testing for bacterial mutagenicity, 25 for gene mutation in mammalian cells, 30 for in vitro cytogenetics, 30 for in vivo cytogenetics, 16 for DNA damage and DNA repair synthesis, and 10 in other types of genotoxicity assays. Twenty-five drugs were tested for genotoxicity in human cells. Concerning carcinogenicity, 22 drugs were tested in mice and 21 in rats, but it should be considered that 14 drugs (no. 2, 12, 13, 19, 20-24, 29, 30, 31, 34, 39 of Table I ) gave negative responses at doses to various extents lower than that recommended by present guidelines, i.e. lower than 25-fold the maximum recommended human daily dose on a milligram per square millimetre basis. Table III provides for each type of assay the number of drugs with positive, negative and discordant results in the same assay.
It is worth noting that the majority of drugs gave a negative result in the various types of genotoxicity assays; the fraction of those giving a positive response was to some extent higher in in vitro cytogenetics assays. With respect to carcinogenesis assays, 16 drugs (no. 1, 4, 8, 13, 17, 19, 20, 22, 24, 26-28, 31, 34, 38, 39 of Table I ) were carcinogenic in mice and 12 drugs (no. 1, 4, 12, 17, 20-22, 26-28, 34, 37 of Table I) were carcinogenic in rats. Six drugs (no. 12, 13, 19, 21, 24, 31 of Table I ) gave discordant results in the two species.
An analysis of the correlation among the results of the various types of genotoxicity assays is shown in Table IV . The percentage of concordant results ranges from a maximum of 100% between bacterial mutagenicity and DNA lesions (binding covalent to DNA, DNA strand breaks, unscheduled DNA synthesis), and DNA lesions and in vivo cytogenetics to a minimum of 60% between DNA lesions and in vitro cytogenetics. The occurrence of discordance between the results of genotoxicity assays has been previously reported. According to Ishidate et al. (14) the 90% of substances negative in the Ames test were positive in the chromosomal aberrations assay, and only 59% of clastogens were also positive in the Ames test.
An analysis of the correlation between the results of the various types of genotoxicity assays and the results of carcinogenicity assays is shown in Table V . The drugs included in this analysis are only those that in the genotoxicity assay considered gave only positive results or only negative or inconclusive results, and in carcinogenesis assays induced tumour development in at least one sex of mice or rats or gave (12, 20-22, 27, 39) Drugs considered as positive are those that gave only positive results. Drugs considered as negative are those that gave only negative or inconclusive results. Discordant indicates the number of drugs that gave both positive and negative or inconclusive results in genotoxicity assays and in carcinogenicity assays performed in the same species. Numbers in parentheses are those of drugs of Table I. under test. In contrast, it has been shown that there are carcinogens that gave negative or equivocal results in the in vivo micronucleus test. Recently Kirkland and Speit (76) examined the published in vivo results of unscheduled DNA synthesis (UDS), transgenic mutation and Comet assay for 67 carcinogens that tested negative in the in vivo micronucleus assay. In general, the UDS test was disappointing giving positive results with ,20% of these carcinogens; the transgenic mutation assay gave positive responses with .50% of the carcinogens, and the Comet assay detected almost 90% of the micronucleus-negative or equivocal carcinogens. Moreover, based on a small number of publications with non-carcinogens, the transgenic mutation and the Comet assays gave negative results with non-carcinogens in 69 and 78% of occasions, respectively. Drugs included in these comparisons are those that in the assay considered gave only positive results or only negative or inconclusive results. In parentheses are indicated the corresponding percentages and the numbers of drugs included in Table I . Finally, Table VI indicates, using the same criteria of inclusion indicated for Table V, the percentages of drugs that, according to results obtained in the various types of genotoxicity assays, may be classified as non-genotoxic noncarcinogens, genotoxic non-carcinogens, non-genotoxic carcinogens and genotoxic carcinogens. These percentages depend on the genotoxicity assay considered. For instance, classified as non-genotoxic non-carcinogens are the 23.5% of drugs that tested negative in bacterial mutagenicity assays and the 8.3% of those that tested negative in gene mutation assays, and as nongenotoxic carcinogens the 87.5% of drugs that tested negative in DNA lesions assays and the 42.9% of those that tested negative in in vitro cytogenetics assays. If we prudently presume that a drug might be considered genotoxic if tested positive in at least one genotoxicity assay and carcinogenic if tested positive in at least one sex of mice or rats, of the 23 drugs with both genotoxicity and carcinogenicity assays, 15 (no. 2, 4, 8, 12, 17, 19, 20, 22, 24, 27, 28, 31, 34, 38, 39 of Table I ) might be classified as genotoxic carcinogens even if they provided in genotoxicity assays contrasting results. Four drugs (no. 13, 21, 26, 37 of Table I ) might be considered nongenotoxic carcinogens. In a quantitative risk assessment the capability of distinguishing between genotoxic and nongenotoxic carcinogens is important for the prediction of the dose-response curve and for the extrapolation of experimental data to relevant levels of human exposure. While threshold models are valid for non-genotoxic carcinogens, a no-effect level usually cannot be expected for genotoxic carcinogens. According to IARC (59) , an agent is classified as probably carcinogenic to humans (Group 2A) when there is limited evidence of carcinogenicity in humans and sufficient evidence of carcinogenicity in experimental animals. Exceptionally, an agent may be classified in this category solely on the basis of limited evidence of carcinogenicity in humans or sufficient evidence of carcinogenicity in experimental animals strengthened by supporting evidence from relevant genotoxicity data. An agent is classified as possibly carcinogenic to humans (Group 2B) when there is limited evidence in humans in the absence of sufficient evidence in experimental animals. It may be also classified in this category when there is inadequate evidence of carcinogenicity in humans or when human data are non-existent, but there is sufficient evidence of carcinogenicity in experimental animals. In some instances, an agent for which there is inadequate evidence or no data in humans but limited evidence of carcinogenicity in experimental animals together with supporting evidence from other relevant data may be placed in Group 2B. On the basis of these indications, chloramphenicol (59) may be considered as probably carcinogenic to humans; griseofulvin (38) , metronidazole (59), zalcitabine and zidovudine (12) are already classified by IARC as possibly carcinogenic to humans and tentatively entecavir, nevirapine and stavudine may be considered in the same Group 2B. All the other drugs, on the basis of retrieved data, should be considered not classifiable as to their carcinogenicity to humans; acyclovir (12) , ampicillin (15) , chloroquine, dapsone, didanosine, isoniazid (59), nitrofurantoin (15) , nitrofurazone (15) and rifampicin (59) have been already classified by IARC in the same group.
Finally, it should be considered that genotoxic carcinogenic effects might be produced in humans by the N-nitroso compounds formed in the gastric environment by the reaction with nitrite of drugs that are theoretically nitrosatable amine drugs (77) . In this respect, it should be considered that ampicillin, chloramphenicol, chloroquine, ethambutol, isoniazid and rifampicin have been found to form N-nitroso compounds by reacting with nitrite. Moreover, genotoxic effects have been found to be produced by the nitrosation mixture or the nitrosation reaction product of chloroquine, ethambutol and isoniazid.
In conclusion, it is evident that the information provided by this survey on the genotoxic and carcinogenic activity of antibacterial, antiviral, antimalarial and antifungal drugs of long-term or frequent intermittent use suggests that for the large majority of the 48 marketed pharmaceuticals considered available data are inadequate for a reliable assessment of the potential genotoxic and carcinogenic risk to humans. Efforts to develop and refine methods for genotoxicity and carcinogenicity testing of pharmaceuticals started 20 years ago, and present guidelines were published in 1996-97 (1) (2) (3) (4) (5) . This explains why for several antibacterial, antiviral, antimalarial and antifungal drugs results of genotoxicity The data indicate the number of non-carcinogens and carcinogens examined in each genotoxicity assay that tested negative-inconclusive (non-genotoxic) and positive (genotoxic) in the same assay. In this analysis were considered as non-carcinogens those drugs that did not increase tumour incidence in mice and/or rats of both sexes and as carcinogens those drugs that increased tumour incidence in at least one sex of mice or rats. Only the drugs that gave a single negative-inconclusive or concordant negative-inconclusive results and the drugs that gave a single positive or concordant positive results in the indicated genotoxicity assay were considered non-genotoxic and genotoxic, respectively, and were included in this analysis.
and carcinogenicity assays recommended by present guidelines were not retrieved. Finally, the usefulness of risk/benefit analysis when using a drug exhibiting a genotoxic and/or carcinogenic activity should be considered, and it is reasonable to suggest that, in the absence of compelling indications for the use of a specific drug, the prescription of a drug devoid of genotoxic and carcinogenic activities is a prudent choice.
